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Background: Depression in adolescence is common and early onset predicts worse outcome in adult-
hood. Studies in adults have suggested a link between higher total 25-hydroxyvitamin D [25(OH)D]
concentrations and lower risk of depression. Objectives: To investigate (a) the association between
serum 25(OH)D2 and 25(OH)D3 concentrations and depressive symptoms in children, and (b) whether
the associations of 25(OH)D2 and 25(OH)D3 are different from, and independent of, each
other. Methods: Prospective cohort study with serum 25(OH)D2 and 25(OH)D3 concentrations mea-
sured at mean age of 9.8 years and depressive symptoms assessed with the Mood and Feelings Ques-
tionnaire by a trained interviewer at the mean ages of 10.6 years (n = 2,759) and 13.8 years
(n = 2,752). Results: Higher concentrations of 25(OH)D3 assessed at mean age 9.8 years were associ-
ated with lower levels of depressive symptoms at age 13.8 years [adjusted risk ratio (RR; 95% confidence
interval (CI)): 0.90 (0.86–0.95)], but not at age 10.6 years [adjusted RR (95% CI): 0.98 (0.93–1.03)] and
with increased odds of decreasing symptoms between age 10.6 and 13.8 years [adjusted RR (95% CI):
1.08 (1.01–1.16)]. Serum 25(OH)D2 concentrations were not associated with depressive symp-
toms. Conclusions: This is the first study in children to suggest that the association between 25(OH)D3
concentrations and depression emerges in childhood. The association is independent of a wide range of
potential confounding factors, and appears to be stronger with greater time separation between
assessment of 25(OH)D3 and assessment of depressive symptoms. Confirmation of our findings in large
prospective studies and trials would be valuable. Keywords: 25-Hydroxyvitamin D, calcium, para-
thyroid hormone, child, depression, ALSPAC.
Introduction
Depression affects 1–6% of adolescents worldwide
and early onset often predicts more serious disease
manifestation in later life (Thapar, Collishaw, Potter,
& Thapar, 2010). Characterisation of modifiable risk
factors that could be used to prevent or delay the
early onset of depression is important. It has been
suggested that higher concentrations of vitamin D
may protect against depression in adults. Depres-
sion rates are higher in winter than in summer
months, which could support a role for vitamin D
(Bertone-Johnson, 2009). Some (Armstrong et al.,
2007; Berk et al., 2007; Eskandari et al., 2007;
Ganji, Milone, Cody, McCarty, & Wang, 2010; Hoo-
gendijk et al., 2008; Jorde, Waterloo, Saleh, Haug, &
Svartberg, 2006, Lee et al., 2010; Schneider, Weber,
Frensch, Stein, & Fritz, 2000; Wilkins, Sheline, Roe,
Birge, & Morris, 2006) but not all (Annweiler et al.,
2010; Herran et al., 2000; Michelson et al., 1996;
Nanri et al., 2009; Pan et al., 2009; Zhao, Ford, Li, &
Balluz, 2010) cross-sectional studies in adults have
found an association between higher serum con-
centrations of 25-hydroxyvitamin D (25(OH)D) and
lower risk of depression in adults. Two prospective
studies found that higher concentration of 25(OH)D
were associated with lower risk of depression in older
adults (May et al., 2010; Milaneschi et al., 2010) and
three randomised controlled trials in selective pop-
ulations had inconsistent findings, with a trial of
vitamin D3 supplements improving depression
symptoms in overweight/obese adults (Jorde, Sneve,
Figenschau, Svartberg, & Waterloo, 2008) but two
further trials of D3 showing no effect on symptoms in
older women with seasonal affective disorder
(Dumville et al., 2006) or on preventing depression
in older women (Sanders et al., 2011).
25(OH)D is a robust and reliable indicator of vita-
min D status, reflecting both dietary intake and
synthesis in skin, which normally accounts for most
of the vitamin D in humans (Seamans & Cashman,
2009). Circulatory total 25(OH)D consists of
25(OH)D3 [metabolite of vitamin D3 synthesised in
skin after ultraviolet B (UVB) exposure and obtained
from animal food sources] and 25(OH)D2 (synthes-
ised from vitamin D2 obtained from plant sources).
25(OH)D3 and 25(OH)D2 are converted to 1,25-
dihydroxyvitamin D3 and D2, the steroid hormones
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that mediate the biological actions of vitamin D. The
former is known to have higher affinity to vitamin D
binding protein and receptor (Glendenning et al.,
2009; Houghton & Vieth, 2006) and with respect to
bone health, vitamin D3 has been suggested to be
more potent than D2 (Finch, Brown, & Slatopolsky,
1999). However, to date no studies have examined
whether associations between these two differ with
respect to depression. Vitamin D, together with
parathyroid hormone (PTH), regulates calcium and
phosphate homoeostasis (Brown, Dusso, & Slato-
polsky, 1999; Mundy & Guise, 1999) and some
(Eskandari et al., 2007; Herran et al., 2000, Hoo-
gendijk et al., 2008; Jorde et al., 2006; May et al.,
2010) but not all (Michelson et al., 1996; Schneider
et al., 2000) studies have reported higher serum PTH
among adults with depression. As the previous
studies have included only adults, it is unknown if
serum 25(OH)D concentrations are associated with
mood in childhood or early adolescence. Examining
this association in childhood/adolescence is impor-
tant because confounding by alcohol, smoking and
mood-altering drugs is somewhat less likely than in
adult studies and because it is increasingly recog-
nised that depression can emerge in childhood/
adolescence (Thapar et al., 2010) and its prevention
may be best started at this age.
The aims of this study were (a) to investigate the
prospective association between serum 25(OH)D2
and 25(OH)D3 concentrations and depressive
symptoms in children, (b) to investigate if the asso-
ciations of 25(OH)D2 and 25(OH)D3 are different,
and (c) to examine whether any associations were
independent of serum PTH, phosphate and calcium
concentrations.
Participants and methods
Population
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a population-based birth cohort from
South West England. The cohort consisted of 14,062
live births from 14,541 enrolled pregnant womenwho
were expected to give birth between 1 April 1991 and
31 December 1992 (Golding, Pembrey, Jones and
ALSPAC Study Team, 2001). From age 7, all children
were invited for anannual assessment of physical and
psychological development. Parents gave informed
consent at enrolment, and ethical approval was
obtained from the ALSPAC Law and Ethics Research
Committee and the National Health Service (NHS)
local research ethics committee.
Single and twin births were included in this study;
the very small number of triplets and quadruplets
were not included for reasons of confidentiality.
Figure 1 shows how the numbers included in the
analyses presented here was derived. Complete data
on outcomes, exposures and confounders were
available from 2,759 and 2,752 children, respec-
tively, for assessment with outcomes at 10.6 years
and with outcomes at 13.8 years.
Outcome
The prevalence of depressive symptoms was evalu-
atedwith theMood andFeelingsQuestionnaire (MFQ)
by a trained interviewer at the mean ages of 10.6 and
13.8 years. The MFQ is a 13-item depression inven-
tory validated for use in 6- to 18-year-olds. Each item
is scored between 0 and 2, resulting to a maximum
score of 26 with higher scores indicating presence of
symptoms of depression. MFQ correlates highly with
more extensive evaluations like the Children’s
Depression Inventory and the Diagnostic Interview
Schedule for Children (Costello & Angold, 1988).
The MFQ scores were positively skewed even after
various transformations so we generated three cat-
egories of the score (0–2, 3–5, ‡ 6), representing
approximate thirds of the distribution. An ordinal
categorical variable was derived to indicate change in
MFQ score category (increase by two categories/
increase by one category/no change/decrease by
one category/decrease by two categories) between
ages 10.6 and 13.8 years.
Exposures and phlebotomy-based covariables
Serum 25(OH)D3, 25(OH)D2, PTH, phosphate and
calcium were assayed on nonfasting blood samples
Figure 1 Flow of participants
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collected at mean age 9.9 years for the majority of
participants (n = 2,130 for MFQ assessed at age
13.8 years and n = 2,493 for MFQ assessed at age
10.6 years). If no samples were available from the
9.9-year assessment, samples from mean age
11.8 years (n = 416) or, second, the 7.6-year
assessments (n = 206 for MFQ assessed at age
13.8 years and n = 266 for MFQ assessed at age
10.6 years) were used. The mean age at sample col-
lection in the whole study sample was 9.8 years
(standard deviation: SD = 0.74). To keep the analy-
ses prospective, we excluded exposure measure-
ments that were taken at 11.8-year clinic when the
outcome was measured at age 10.6 years.
Following collection, samples were immediately
spun, frozen and stored at )80 C. Assays were
performed after a maximum of 12 years in storage
with no previous freeze-thaw cycles. 25(OH)D3,
25(OH)D2 and deuterated internal standard were
extracted from serum samples, following protein
precipitation, using Isolute C18 solid phase extrac-
tion cartridges. Potential interfering compounds
were removed by initial elution with 50% methanol
followed by elution of the vitamins using 10% tetra-
hydrofuran in acetonitrile. Dried extracts were
reconstituted prior to injection into a high-pressure
liquid chromatography tandem mass spectrometer
(Waters Acuity, Manchester, UK). The following
transitions (mass to charge ratio) in multiple reac-
tion mode were used: 413.2 > 395.3, 401.1 > 383.3
and 407.5 > 107.2 for 25(OH)D2, 25(OH)D3, and
hexa-deuterated 25(OH)D3 respectively. Interassay
coefficients of variation for the assay were < 10%
across a working range of 1–250 ng/ml for both
25(OH)D3 and 25(OH)D2. Measurements were per-
formed in a laboratory meeting the performance
target set by the Vitamin D External Quality
Assessment Scheme (DEQAS) Advisory Panel for
25(OH)D assays.
Total serum calcium, phosphate and albumin
concentrations were measured by standard labora-
tory methods on Roche Modular analysers (Roche
Diagnostics Ltd, West Sussex, UK). Serum calcium
was adjusted for albumin using a normogram of
calcium and albumin distributions of the samples
analysed in the clinical chemistry laboratory where
the measurements were performed and albumin-
adjusted calcium was used in all statistical analyses.
Intact parathyroid hormone [iPTH(1–84)] was mea-
sured by electrochemiluminescent immunoassay on
Elecsys 2010 immunoanalyzer (Roche, Lewes, UK).
Interassay coefficient of variation was < 6% from 2 to
50 pmol/L. The assay sensitivity was 1 pmol/L.
Confounding factors
We considered gender, age, ethnicity (white, non-
white), head of household occupational social class,
maternal and paternal education, family history of
depression or schizophrenia, UVB exposure, body
mass index (BMI) and cognitive function to be
important confounders because of their known
associations with 25(OH)D3 concentrations and
depressive symptoms. We also adjusted for pubertal
stage as this might affect depressive symptoms and
25(OH)D3. Data on head of household occupational
social class, ethnicity, parents’ education and family
history of depression and schizophrenia were
obtained from parent-completed questionnaires.
Time spent outdoors during summer months on
school days, school weekends and holidays was re-
ported as None, 1 hr/day, 1–2 hr/day and 3 or more
hr/day in parent-completed questionnaires at mean
age of 8.5 years. Responses were coded as follows:
None = 0, 1 = 1, 1–2 = 1.5 and 3 = 5. Average hours
spent outdoors per summer day (1 June–31 August)
were calculated using term dates from Bristol City
Council’s Education Committee term dates for 2001–
2002 (summer term 1 June–24 July, holidays 24
July–31 August). Information on protection from
UVB exposure (use of sunblock, covering clothing or
hat and avoidance of midday sun) were obtained
from the same questionnaires. A summary variable
for UVB protection score was derived by scoring the
responses to questions on use of sunblock, covering
clothing or hat and avoidance of midday sun as
Always = 3, Usually = 2, Sometimes = 1, Never = 0
and summing these scores. This gives a single vari-
able that ranges from 0 to 12, with 0 indicating the
least meticulous protection from UVB.
Height and weight were measured at the same time
as blood samples for obtaining 25(OH)D3 and other
assays and were used to calculate BMI. Total IQ
score in Wechsler Intelligence Scale for Children
(WISC–III UK version) was assessed at mean age 8.5.
Puberty stage was assessed by parental report using
Tanner staging (Tanner, 1962) of pubic hair, breast
and genitalia development on repeat occasions. In
our analyses, we used data from the questionnaire
closest to the time of phlebotomy for the exposures
for each child.
25(OH)D3 concentrations had displayed a sinu-
soidal seasonal variation (Figure 2). In order to
derive a value of 25(OH)D3 for each participant that
was accurately adjusted for the seasonal effects of
when the sample was taken, we used linear regres-
sion with date of blood sampling as the independent
variable and loge 25(OH)D3 as the outcome (depen-
dent) variable and with trigonometric sine and cosine
functions. 25(OH)D3 was loge transformed in this
regression model to ensure that the residuals in the
sine–cosine regression were approximately normally
distributed. The residuals from this regression are
the participants logged 25(OH)D3 having adjusted
for seasonal differences in when the sample was
taken. This seasonal adjusted 25(OH)D3 variable
represents a participants average 25(OH)D3 across
seasons and is the main 25(OH)D3 exposure
measurement used in our analyses [we also present
associations without this adjustment]. There was no
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strong seasonal variation in 25(OH)D2 concentra-
tions.
Statistical analyses
Statistical analyses were conducted with STATA 11.0
(Stata Corp LP, College Station, TX).
To include all participants on whom a 25(OH)D2
was assayed, those with a value below the detectable
limit of the assay (0.5 ng/ml) were given a value of
0.5 ng/ml and indicated using a binary covariable in
all regression models. Serum 25(OH)D3, 25(OH)D2,
calcium, phosphate and PTH concentrations were
age- and gender-standardised using the internal
cohort data with age in 1-month categories.
The association of potential confounders with
serum 25(OH)D3, 25(OH)D2, calcium, phosphate and
PTH concentrations was assessed with linear
regression and associations of confounders with
depressive symptoms with ordered logistic regres-
sion. We investigated the linearity of associations
between 25(OH)D3 and 25(OH)D2 and depressive
symptoms by splitting the 25(OH)D variables into
fifths of their distribution and graphically examining
the odds of depressive symptoms across these fifths.
We statistically tested for linearity by obtaining a p
value for linear trend from a regression model in
which these fifths were entered as a continuous
score (1–5). Deviation from linearity was assessed
with a likelihood ratio test comparing regression
models in which the fifths were entered as categories
(four indicator variables) and one in which they were
entered as a continuous score.
The main analyses assessing associations of sea-
sonally adjusted 25(OH)D3 and 25(OH)D2 with out-
comes were done with a nonparametric bootstrap
procedure (10,000 replications) in conjunction with
ordered logistic regression using bsample and ologit
commands in STATA. The bootstrapping procedure
(Efron & Tibshirani, 1986) enabled us to statistically
compare associations of 25(OH)D3 to those of
25(OH)D2. The difference between the effect of
25(OH)D3 and 25(OH)D2 was calculated from the
bootstrap replicate distribution To numerically
compare the associations of two forms of 25(OH)D,
we scaled them the same by multiplying the beta
coefficients from the regression models by loge(2).
The results are interpreted as the difference in odds
of MFQ between the lowest and middle or middle and
highest MFQ score per doubling of exposure.
In addition to examining associations with
25(OH)D2 and 25(OH)D3 on a continuous scale, we
also examined the association between total
25(OH)D deficiency and insufficiency and depressive
symptoms. Total 25(OH)D was calculated by sum-
ming 25(OH)D2 and 25(OH)D3 and insufficiency was
defined as a value below 30 ng/ml and deficiency
below 20 ng/ml (Holick, 2007). Finally, in a sensi-
tivity analysis we examined the association of
25(OH)D3 that was not adjusted for seasonal varia-
tion with outcomes. All association analyses were
performed for both genders combined as there was
no strong statistical evidence for Gender · Exposure
interaction (p ‡ .20).
Results
The mean (interquartile range) serum concentrations
of season-adjusted 25(OH)D3 and 25(OH)D2 were
24.9 (24.7–25.1) and 1.3 (0.5–2.7) ng/ml, respec-
tively. The median (interquartile range) of serum
phosphate, calcium and PTH were 1.54 (1.43–
1.64) mmol/L, 2.38 (2.31–2.44) mmol/L and 4.5
(3.4–5.8) pmol/L respectively. Other characteristics
of the participants are shown in Table S1.
Table S2 shows the associations of 25(OH)D3,
25(OH)D2 phosphate, calcium and PTH concentra-
tions with potential confounders. Those of nonwhite
ethnicity had higher PTH and lower 25(OH)D3 con-
centrations. BMI was negatively associated with
serum 25(OH)D3 and 25(OH)D2 concentrations and
positively with PTH concentrations. Higher socio-
economic position of parents was associated with
lower concentrations of calcium and 25(OH)D2 and
higher concentrations of 25(OH)D3. Less meticulous
protection from UVB was associated with lower PTH
concentrations and higher 25(OH)D3 concentrations.
Children who spent more time outdoors during
summer had higher 25(OH)D3 and 25(OH)D2 con-
centrations. Children with family history of psychi-
atric problems had lower 25(OH)D3 and calcium
concentrations. Those with more advanced puberty
stage had lower 25(OH)D3 concentrations and higher
calcium concentrations.
Table S3 summarises the associations of con-
founders and depressive symptoms at ages 10.6 and
13.8 years. Higher socioeconomic position and IQ
were associated with lower risk of depressive symp-
toms at age 10.6 years and higher BMI with higher
risk of depressive symptoms at age 13 years. Chil-
dren who spent more time outdoors during summer
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Figure 2 Seasonal variation in serum 25(OH)D3 concentrations
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had lower risk of depressive symptoms at age
13.8 years. Children with family history of psychi-
atric problems had higher risk of depressive symp-
toms at both ages.
The associations of 25(OH)D3 and 25(OH)D2 with
depressive symptoms were either linear or null, with
no strong evidence of deviation from linearity or
suggestion of a threshold association (Figure 3).
Table 1 shows the prospective associations between
serum 25(OH)D3, 25(OH)D2, phosphate, calcium
and PTH concentrations and depressive symptoms
at ages 10.6 and 13.8 years. Higher concentrations
of 25(OH)D3 were associated with lower risk of
depressive symptoms at age 13.8 years but not at
age 10.6 years. 25(OH)D2 was not associated with
depressive symptoms at either age. There was sta-
tistical evidence that the association of 25(OH)D3
with depressive symptoms at age 13.8 years differed
from the association of 25(OH)D2 with the same
outcome (p £ .001), but there was no evidence of
difference in associations of 25(OH)D3 and 25(OH)D2
with symptoms at age 10.6 years (p = .81). There
was some suggestion that higher concentrations of
PTH were associated with lower risk of depressive
symptoms at age 13.8 years after adjusting for all
confounders and other measured analytes, but
(A) (B)
(D)(C)
Figure 3 Odds of depressive symptoms at age 10.6 years (A and B) and age 13.8 years (C and D) by fifths of the distribution of 25(OH)D3
(A and C) and 25(OH)D2 (B and D)
Table 1 Prospective association of 25(OH)D3, 25(OH)D2, phosphate, albumin-adjusted calcium and parathyroid hormone con-
centrations with depressive symptoms assessed by short Mood and Feelings Questionnaire at age 10.6 years (n = 2,759; exposures
assessed at mean age 9.2 years) and age 13.8 years (n = 2,752; exposures assessed at mean age 9.8 years)
Outcome Exposure
OR for category change per doubling of exposure (95% CI)
Model 1a Model 2b Model 3c
Depressive symptoms
at age 10.6 years
25(OH)D3 0.98 (0.93, 1.03) 0.98 (0.93, 1.03) 0.98 (0.93, 1.03)
25(OH)D2 1.02 (0.94, 1.10) 1.01 (0.93, 1.10) 0.99 (0.94, 1.04)
Albumin-adjusted calcium 1.02 (0.97, 1.07) 1.01 (0.97, 1.06) 1.00 (0.95, 1.05)
Phosphate 1.03 (0.98, 1.08) 1.04 (0.99, 1.09) 1.04 (0.98, 1.09)
Parathyroid hormone 0.98 (0.93, 1.03) 0.98 (0.94, 1.03) 0.97 (0.93, 1.03)
Depressive symptoms
at age 13.8 years
25(OH)D3 0.90 (0.86, 0.94) 0.91 (0.86, 0.95) 0.90 (0.86, 0.95)
25(OH)D2 1.02 (0.95, 1.11) 1.03 (0.95, 1.12) 1.02 (0.97, 1.08)
Albumin-adjusted calcium 0.99 (0.94, 1.04) 1.00 (0.95, 1.04) 0.99 (0.94, 1.04)
Phosphate 1.01 (0.97, 1.06) 1.02 (0.97, 1.06) 1.02 (0.98, 1.07)
Parathyroid hormone 0.99 (0.94, 1.03) 0.98 (0.93, 1.02) 0.96 (0.91, 1.01)
OR, odds ratio.
aModel 1 is unadjusted (the exposures are standardised for age and gender and 25OHD3 is adjusted for season and ethnicity).
bModel 2 is adjusted for ethnicity, head of household social class, mothers and partners education, time spent outdoors during
summer (age 8.5 years), UVB protection score, WISC IQ score at 8.5 years, BMI, family history of psychiatric problems and puberty
stage. cModel 3 is adjusted for Model 2 plus serum concentrations of other hormones/metabolites which are related vitamin D
homeostasis [e.g. association of 25(OH)D3 is adjusted for 25(OH)D2, phosphate, albumin-adjusted calcium and parathyroid
hormone].
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confidence intervals were wide and included the null
value. Other exposures were not associated with
depressive symptoms.
The associations of 25(OH)D3 concentrations
which were not adjusted for seasonality (Table S4)
and of total 25(OH)D (Table S5) were identical to
those of seasonal adjusted 25(OH)D3. Consistent
with these findings depressive symptoms at age
10.6 years did not differ between those with total
25(OH)D deficiency or total 25(OH)D insufficiency,
whereas those with either deficiency or insufficiency
had increased risk of depressive symptoms of 20–
30% at age 13.8 (Table 2).
Table 3 shows change in depressive symptoms
between age 10.6 and 13.8 years. We present these
for all participants with valid responses to the MFQ
at both ages (N = 4,487) and also those with com-
plete data on MFQ at both ages and all covariables
used in any multivariable models (N = 1,815). The
distributions of the change variables are very similar
in these two groups. The most common occurrence
was for participants to remain stable over time or for
depressive symptoms to have increased by one cat-
egory. The least common was for a decrease in
depressive symptoms by two categories.
Table 4 shows the associations of serum concen-
trations of 25(OH)D3, 25(OH)D2, calcium, phosphate
and PTH with changes in depressive symptom cate-
gory. A doubling in 25(OH)D3 concentrations was
associated with a 9% increased odds of depressive
symptoms decreasing between age 10.6 and
13.8 years, with little effect of adjustment for
potential confounding factors. 25(OH)D2, calcium,
phosphate or PTH were not associated with change
in depressive symptoms over time and there was
statistical evidence of a different association of
25(OH)D3 and 25(OH)D2 with change in depressive
symptoms (p = .012).
Discussion
In our prospective study of children, we have found
higher concentrations of season-adjusted 25(OH)D3
assessed at mean age 9.8 years to be associated with
lower levels of depressive symptoms at age
13.8 years and with increased odds of decreasing
symptoms between age 10.6 and 13.8 years. These
associations were independent of a wide range of
potential confounders, as well as of 25(OH)D2, cal-
cium, phosphate and PTH concentrations, which
were not strongly associated with depressive symp-
toms at either age. We also found statistical evidence
that the association of 25(OH)D3 with depressive
symptoms was stronger than that of 25(OH)D2. The
association of 25(OH)D3 with depressive symptoms
was linear across the distribution of 25(OH)D3 con-
centrations, suggesting that even amongst those
with what would be considered normal concentra-
tions, an increase might result in somewhat lower
depressive symptoms (if our findings are in future
studies shown to represent causal effects). Consis-
tent with these findings, and reflecting the fact that
25(OH)D3 is the biggest contributor to total 25(OH)D,
we found that risk of depressive symptoms was
greater at 13.8 years in those with total 25(OH)D
deficiency or total 25(OH)D insufficiency.
To our knowledge, this is the first prospective
study to examine this association in children. Our
findings in this cohort of children are consistent with
findings from the two prospective studies in adults
(May et al., 2010; Milaneschi et al., 2010) and from
Table 2 Prospective association of total 25(OH)D deficiency and insufficiency with depressive symptoms assessed by short Mood
and Feelings Questionnaire at age 10.6 years (n = 2,759; vitamin D status assessed at mean age 9.2 years) and age 13.8 years
(n = 2,752; vitamin D status assessed at mean age 9.8 years)
Outcome Exposure
OR for category decrease per doubling of exposure (95% CI)
Model 1a Model 2b Model 3c
Depressive symptoms
at age 10.6 years
Vitamin D deficiency 0.97 (0.87, 1.08) 0.97 (0.88, 1.09) 0.98 (0.87, 1.09)
Vitamin D insufficiency 1.00 (0.90, 1.11) 1.02 (0.91, 1.16) 1.01 (0.90, 1.13)
Depressive symptoms
at age 13.8 years
Vitamin D deficiency 1.20 (1.08, 1.33) 1.19 (1.07, 1.33) 1.21 (1.08, 1.36)
Vitamin D insufficiency 1.26 (1.12, 1.42) 1.26 (1.13, 1.41) 1.27 (1.12, 1.42)
OR, odds ratio.
aModel 1 is unadjusted. bModel 2 is adjusted for ethnicity, age, gender, head of household social class, mothers and partners
education, time spent outdoors during summer (age 8.5 years), UVB protection score, WISC IQ score at 8.5 years, BMI, maternal
history of psychiatric problems and puberty stage. cModel 3 is adjusted for Model 2 plus serum concentrations of phosphate,
albumin-adjusted calcium and parathyroid hormone.
Table 3 Changes in depressive symptom categories assessed
by change in Mood and Feelings Questionnaire (MFQ) score
category between age 10.6 and 13.8 years (in all participants
with MFQ data at both ages (N = 4,487) and those with com-
plete data on MFQ at both ages and on all other variables in-
cluded in any multivariable analyses (N = 1,815)
Category
All participants
with valid MFQ
data at
both ages,
n (%)
Participants
with complete
data on MFQ at
both ages and all
other covariables,
n (%)
Increase by two categories 582 (13.0) 247 (13.6)
Increase by one category 1,285 (28.7) 534 (29.4)
No change 1,285 (28.7) 520 (28.7)
Decrease by one category 1,037 (23.1) 421 (23.2)
Decrease by two categories 298 (6.6) 93 (5.2)
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one randomised controlled trial that examined the
effect of vitamin D3 supplementation on depressive
symptoms in adults (Jorde et al., 2008).
The association of 25(OH)D3 with depressive
symptoms in children only emerged with symptoms
measured 3 years after exposure assessment, and
was not present when symptoms were assessed just
1 year after exposure assessment. One might expect
a stronger association with the earlier age, possibly
in part because of reverse causality [i.e. depressive
symptoms resulting in less outdoor activity and
hence reduced vitamin 25(OH)D3 concentrations]. It
is possible that children with higher concentrations
of 25(OH)D3 at age 9.8 years have on average higher
concentrations over the subsequent 3 years and that
the inverse association with depressive symptoms
requires an accumulation of consistent concentra-
tions. Alternatively, factors other than 25(OH)D3 but
that are associated with it and accumulate over time
(e.g. outdoor physical activity) might explain the
association. The risk factors for childhood–onset
depression may also be different from those of ado-
lescence–onset depression (Jaffee et al., 2002).
Lastly, it is possible that the biological pathways
linking 25(OH)D3 to depression involve a chain of
effects that take some time to emerge.
The stronger association of 25(OH)D3 compared to
25(OH)D2 could be a chance finding. The difference
could also reflect possible greater residual con-
founding by, for example, different dietary patterns
associated with 25(OH)D2 and 25(OH)D3 or outdoor
physical activity, which will affect D3 more than D2;
whilst we have attempted to adjust for a wide range
of potential confounding factors residual confound-
ing is possible. Lastly, the different associations
could be explained by D3 being truly more potent at
preventing depressive symptoms than D2. This
finding requires further replication in other studies
before we can conclude that D3 is more strongly
associated with depressive symptoms than is D2.
Vitamin D receptors are expressed throughout the
brain and both 25(OH)D3 and 25(OH)D2 cross the
blood–brain barrier (Eyles, Smith, Kinobe, Hewison,
& McGrath, 2005). Animal studies have shown that
vitamin D is essential for normal neurogenesis (Cui,
McGrath, Burne, Mackay-Sim, & Eyles, 2007),
learning ability and behaviour in rodents (Becker,
Eyles,McGrath,&Grecksch, 2005;Eyles et al., 2006;
Harms, Eyles, McGrath, Mackay-Sim, & Burne,
2008), but currently it is unknown if the neural ac-
tions of vitamin D metabolites affect monoamine
concentrations, hypothalamic–pituitary–adrenal axis
responsiveness to stress or other mechanisms in-
volved in depression (Belmaker & Agam, 2008).
Contrary to previous studies showing an associa-
tion between higher PTH concentrations and
depression in adults (Hoogendijk et al., 2008; May
et al., 2010), serum concentrations of PTH were not
strongly associated with depressive symptoms in
children in our study. The differences between our
results and these previous studies in adults could be
explained by differences in outcome measurement
and study sample or could reflect real differences in
these associations by age.
Study strengths and limitations
To our knowledge, this is the first study to examine
these associations in children and is one of the few
studies to examine them prospectively. We had a
large sample size and were able to examine potential
confounding by a wide range of characteristics and
study the different effects of 25(OH)D3 and
25(OH)D2. We also used self-reported, rather than
parent-reported depressive symptoms. This is
important because parent-reported scores do not
reveal depressive symptoms as early as self-reported
measures (Cole et al., 2002). Consistent with other
prospective cohort studies there has been sub-
stantial attrition over time with those who continued
to attend the follow-up clinics being more likely to be
from higher socioeconomic backgrounds (Golding,
Pembrey, Jones and ALSPAC Study Team, 2001).
Twenty-seven per cent of our study population had
Table 4 Prospective association of 25(OH)D3, 25(OH)D2, phosphate, albumin-adjusted calcium and parathyroid hormone con-
centrations (assessed at mean age 9.2 years) with decrease in depressive symptoms [N = 1,815; five categories: increase by two
categories (reference); increase by one category; no change, decrease by one category: decrease by two categories]
Exposure
OR for category decrease per doubling of exposure (95% CI)
Model 1a Model 2b Model 3c
25(OH)D3 1.09 (1.02, 1.16) 1.08 (1.01, 1.16) 1.08 (1.01, 1.16)
25(OH)D2 0.97 (0.88, 1.07) 0.96 (0.86, 1.06) 0.95 (0.90, 1.01)
Albumin-adjusted calcium 1.03 (0.97, 1.09) 1.01 (0.96, 1.08) 1.01 (0.96, 1.08)
Phosphate 0.99 (0.94, 1.05) 0.99 (0.94, 1.05) 0.99 (0.93, 1.05)
Parathyroid hormone 0.97 (0.92, 1.03) 0.98 (0.93, 1.04) 0.99 (0.93, 1.05)
OR, odds ratio.
aModel 1 is unadjusted (the exposures are standardised for age and gender and 25OHD3 is adjusted for season and ethnicity).
bModel 2 is adjusted for ethnicity, head of household social class, mothers and partners education, time spent outdoors during
summer (age 8.5 years), UVB protection score, WISC IQ score at 8.5 years, BMI, maternal history of psychiatric problems and
puberty stage. cModel 3 is adjusted for Model 2 plus serum concentrations of other hormones/metabolites which are related vitamin
D homeostasis (e.g. association of 25(OH)D3 is adjusted for 25(OH)D2, phosphate, albumin-adjusted calcium and parathyroid
hormone.
doi:10.1111/j.1469-7610.2011.02518.x 25-Hydroxyvitamin D and depression in childhood 763
 2011 The Authors. Journal of Child Psychology and Psychiatry  2011 Association for Child and Adolescent Mental Health.
total 25(OH)D concentration below 20 ng/ml so the
results are likely to apply to other populations with
high prevalence of low 25(OH)D concentrations
(Lips, 2010; Mansbach, Ginde, & Camargo, 2009).
Depressive symptoms were analysed as a categor-
ical variable instead of a continuous score. Thismight
have lost some refinement, but this was necessary
due to highly skewed distribution. Serum 25(OH)D3,
D2, phosphate, calcium and PTHwere measured on a
single occasion and this may not accurately reflect
usual status (Schram et al., 2007). However, previ-
ous epidemiological studies in adults (including with
bone phenotypes for which these exposures have
established biological relationships) also use single
measurements and for season-specific vitamin D
status over a longer time, a single measure is likely to
be adequate (Hofmann, Yu, Horst, Hayes, & Purdue,
2010) and serum calcium concentrations are nor-
mally maintained within relatively narrow limits in
humans (Parfitt, 1987). As noted above, our results
do not imply causality and the association of
25(OH)D3 with depressive symptoms 3 years later
might be explained by residual confounding.
Conclusions
Our results suggest that the association between
25(OH)D3 concentrations and depression emerges in
childhood. The association is independent of a wide
range of potential confounding factors, and appears
to be stronger with greater time separation between
assessment of 25(OH)D3 and that of depressive
symptoms. Given the importance of depression in
childhood and adolescence and the relative ease with
which 25(OH)D3 could be increased through sup-
plementation, randomised controlled trials to assess
the effectiveness of this for prevention of depressive
symptoms in this age group would be appropriate.
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Key points
• Depression in adolescence is common and early onset predicts worse outcome in adulthood.
• Previous, mainly cross-sectional studies in adults have suggested a link between higher total 25-hydroxyvi-
tamin D [25(OH)D] concentrations and lower risk of depression.
• Findings from this first prospective study in children suggest that the linear association between 25(OH)D
concentrations and depression emerges in childhood/early adolescence and is driven by the 25(OH)D3 form.
• 25(OH)D2 concentrations were not associated with depressive symptoms.
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